[{"id":"acaf9a0f-a467-43c2-8f34-dc61f9d4f9d3","acronym":"OMICC","url":"https://clinicaltrials.gov/study/NCT03661047","created_at":"2021-01-18T17:57:51.957Z","updated_at":"2024-07-02T16:36:20.624Z","phase":"Phase 2","brief_title":"OMega-3 Fatty Acid for the Immune Modulation of Colorectal Cancer","source_id_and_acronym":"NCT03661047 - OMICC","lead_sponsor":"Massachusetts General Hospital","biomarkers":" PD-L1 • CD8 • PD-1 • IL6 • LAG3 • TNFA • CTLA4 • HAVCR2 • TIGIT • IL10 • CCL2 • FOXP3 • ITGA2","pipe":"","alterations":" ","tags":["PD-L1 • CD8 • PD-1 • IL6 • LAG3 • TNFA • CTLA4 • HAVCR2 • TIGIT • IL10 • CCL2 • FOXP3 • ITGA2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e icosapent ethyl"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 11/30/2019","start_date":" 11/30/2019","primary_txt":" Primary completion: 11/30/2021","primary_completion_date":" 11/30/2021","study_txt":" Completion: 11/30/2021","study_completion_date":" 11/30/2021","last_update_posted":"2021-11-17"},{"id":"31408214-b847-4d3f-83d3-8b209d35559e","acronym":"","url":"https://clinicaltrials.gov/study/NCT01099631","created_at":"2022-12-17T21:58:10.265Z","updated_at":"2024-07-02T16:36:43.035Z","phase":"Phase 1","brief_title":"IL-2 Expressing, Attenuated Salmonella Typhimurium in Unresectable Hepatic Spread","source_id_and_acronym":"NCT01099631","lead_sponsor":"Masonic Cancer Center, University of Minnesota","biomarkers":" ITGA2","pipe":"","alterations":" ","tags":["ITGA2"],"overall_status":"Completed","enrollment":" Enrollment 22","initiation":"Initiation: 04/01/2010","start_date":" 04/01/2010","primary_txt":" Primary completion: 01/01/2014","primary_completion_date":" 01/01/2014","study_txt":" Completion: 06/01/2014","study_completion_date":" 06/01/2014","last_update_posted":"2020-07-20"}]